Cellyan Biotechnology (HKPD) Long-Term Deferred Tax (2024)

Cellyan Biotechnology (HKPD) reported Long-Term Deferred Tax of $2.2 million for Q3 2024, up 71.54% quarter-over-quarter from $1.3 million in Q1 2024.

Cellyan Biotechnology (HKPD) Long-Term Deferred Tax (2024) Analysis & Trends

Cellyan Biotechnology (HKPD) has 1 years of Long-Term Deferred Tax data on file, last reported at $2.2 million in Q3 2024.

  • Long-Term Deferred Tax for Q3 2024 came in at $2.2 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $2.2 million (changed N/A YoY), and the FY2024 annual result was $1.3 million, changed N/A from the prior year.
  • Long-Term Deferred Tax improved to $2.2 million in Q3 2024 per HKPD's latest filing, from $1.3 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $2.2 million in Q3 2024 and troughed at $1.3 million in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Akso Health 2,315,158.81 Bn 2,315,158.63 Bn -
2 Mckesson 92.76 Bn 89.18 Bn 4.04 Bn
3 Cencora 52.82 Bn 50.83 Bn 3.59 Bn
4 Cardinal Health 52.17 Bn 48.39 Bn 2.50 Bn
5 Henry Schein 9.19 Bn 9.71 Bn 1.07 Bn
6 Accendra Health 246.88 Mn -90.00 Mn 312.39 Mn
7 Edap Tms 161.92 Mn 146.92 Mn 8.15 Mn
8 111 107.47 Mn 25.61 Mn 23.58 Mn
9 Cosmos Health 9.42 Mn 7.26 Mn 1.38 Mn
10 Cellyan Biotechnology 5.69 -2.48 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2024 2.16 Mn
Mar 31, 2024 1.26 Mn